- Home
- QNCX vs ORMP Comparison
QNCX vs ORMP Comparison
Compare QNCX & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- ORMP
- Stock Information
- Founded
- QNCX 2012
- ORMP 2002
- Country
- QNCX United States
- ORMP United States
- Employees
- QNCX N/A
- ORMP N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- ORMP Biotechnology: Pharmaceutical Preparations
- Sector
- QNCX Health Care
- ORMP Health Care
- Exchange
- QNCX Nasdaq
- ORMP Nasdaq
- Market Cap
- QNCX 47.7M
- ORMP N/A
- IPO Year
- QNCX 2019
- ORMP N/A
- Fundamental
- Price
- QNCX $1.61
- ORMP $2.18
- Analyst Decision
- QNCX Strong Buy
- ORMP Hold
- Analyst Count
- QNCX 5
- ORMP 1
- Target Price
- QNCX $8.00
- ORMP N/A
- AVG Volume (30 Days)
- QNCX 352.5K
- ORMP 77.2K
- Earning Date
- QNCX 08-12-2025
- ORMP 08-15-2025
- Dividend Yield
- QNCX N/A
- ORMP N/A
- EPS Growth
- QNCX N/A
- ORMP N/A
- EPS
- QNCX N/A
- ORMP N/A
- Revenue
- QNCX N/A
- ORMP $2,000,000.00
- Revenue This Year
- QNCX N/A
- ORMP N/A
- Revenue Next Year
- QNCX N/A
- ORMP N/A
- P/E Ratio
- QNCX N/A
- ORMP N/A
- Revenue Growth
- QNCX N/A
- ORMP 196.74
- 52 Week Low
- QNCX $0.51
- ORMP $1.82
- 52 Week High
- QNCX $2.45
- ORMP $3.09
- Technical
- Relative Strength Index (RSI)
- QNCX 64.95
- ORMP 49.72
- Support Level
- QNCX $1.48
- ORMP $2.10
- Resistance Level
- QNCX $1.68
- ORMP $2.25
- Average True Range (ATR)
- QNCX 0.14
- ORMP 0.09
- MACD
- QNCX 0.02
- ORMP 0.00
- Stochastic Oscillator
- QNCX 85.71
- ORMP 63.16
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.